NICE approves vedolizumab for Crohn's disease

The integrin inhibitor vedolizumab (Entyvio) has been approved by NICE for use in moderately to severely active Crohn's disease after prior therapy.

Vedolizumab targets α4β7 integrin, which is responsible for the recruitment of white blood cells to inflamed bowel tissue. | SCIENCE PHOTO LIBRARY
Vedolizumab targets α4β7 integrin, which is responsible for the recruitment of white blood cells to inflamed bowel tissue. | SCIENCE PHOTO LIBRARY

NICE has deemed that patients eligible for NHS treatment with vedolizumab are those with moderate to severe disease who have failed treatment with a tumour necrosis factor (TNF) inhibitor, or for whom such treatment is unsuitable.

Further information
NICE technology appraisal TA352
Patients should continue treatment with vedolizumab until the drug stops working or surgery is needed, or for 12 months, whichever is shorter. Patients should be reassessed at 12 months and treatment continued only if there is clear evidence of clinical benefit.

For patients who achieve complete remission by 12 months consideration should be given to stopping treatment, with the option to resume if a relapse occurs. Patients continuing with treatment past the initial 12 months should be reassessed at least annually to determine whether continued treatment is justified.

NHS approval was granted on the basis that the drug is supplied by the manufacturer with the discount agreed in the patient access scheme.

NICE has also approved vedolizumab for use in moderately to severely active ulcerative colitis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more